[ CAS No. 1314319-10-2 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 1314319-10-2 * Storage: {[proInfo.prStorage]}

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 1314319-10-2 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 1314319-10-2 ]

SDS Specification

Alternatived Products of [ 1314319-10-2 ]

Product Details of [ 1314319-10-2 ]

CAS No. :	1314319-10-2	MDL No. :
Formula :	C₂₁H₂₉BrN₂O₂	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	-
M.W :	421.37	Pubchem ID :	-
Synonyms :

Safety of [ 1314319-10-2 ]

Signal Word:		Class:
Precautionary Statements:		UN#:
Hazard Statements:		Packing Group:

Application In Synthesis of [ 1314319-10-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 1314319-10-2 ]

[ 1314319-10-2 ] Synthesis Path-Downstream 1~8

1
[ 896464-16-7 ]
[ 34598-49-7 ]
[ 1314319-10-2 ]
tert-butyl 2-((1S)-5-bromo-2,3-dihydro-1H-inden-1-yl)-2,7-diazaspiro[3.5]nonane-7-carboxylate [ No CAS ]

Reference： [1]Tetrahedron Letters,2011,vol. 52,p. 3618 - 3620

2
[ 7554-65-6 ]
[ 1314319-10-2 ]
[ 1334785-22-6 ]

Yield	Reaction Conditions	Operation in experiment
79%	With 5-(di-tert-butylphosphino)-1?, 3?, 5?-triphenyl-1?H-[1,4?]bipyrazole; caesium carbonate;tris-(dibenzylideneacetone)dipalladium(0); In 1,4-dioxane; at 100℃;Inert atmosphere;	Preparation of 2-[(R)-5-(4-Methyl-pyrazol-1-yl)-indan-1-yl]-2,7-diaza-spiro[3.5]honane-7-carboxylic acid tert-butyl ester (8-1a) In a sealable reaction tube was combined 2-(R)-5-bromo-indan-1-yl)-2,7-diaza-spiro[3.5]nonane-7-carboxylic acid tert-butyl ester (3-1a, 300 mg, 0.71 mmol), <strong>[7554-65-6]4-methyl-1H-pyrazole</strong> (88 mg, 1.07 mmol), tris(dibenzylideneacetone)dipalladium (65 mg, 0.071 mmol), 5-(di-tert-butyl-phosphanyl)-1',3',5'-triphenyl-1'H-[1,4']bipyrazolyl (72 mg, 0.14 mmol), cesium carbonate (377 mg, 1.07 mmol) and a stir bar. Anhydrous 1,4-dioxane (3 mL) was added and the mixture was purged with nitrogen for 10 minutes. The reaction was sealed and heated at 100 C. overnight. The reaction was cooled to room temperature, opened, and diluted with 150 mL ethyl acetate. The organic solution was washed with 100 mL water, dried (MgSO4), filtered through a plug of Celite and concentrated in vacuo to give a yellow oil. Purification on an ISCO (Teledyne Isco Inc., Lincoln Nebr.) silica column eluting with a 0-100% ethyl acetate in heptanes gradient provided 239 mg (79%) of the title compound (8-1a) as a yellow solid. MS (ES+) 423.0 (M+H)+. 1H NMR (CDCl3) delta 1.42 (s, 9H), 1.62-1.70 (m, 4H), 1.85-1.96 (m, 1H), 2.09-2.16 (m, 4H), 2.81 (dd, 1H), 3.02 (dd, 1H), 3.06-3.15 (m, 4H), 3.22-3.35 (m, 4H), 3.87-3.91 (m, 1H), 7.27 (d, 1H), 7.39 (dd, 1H), 7.45-7.51 (m, 2H), 7.63 (s, 1H).
	With 5-(di-tert-butylphosphino)-1?, 3?, 5?-triphenyl-1?H-[1,4?]bipyrazole; tris-(dibenzylideneacetone)dipalladium(0); caesium carbonate; In 1,4-dioxane; at 100℃; for 18h;Inert atmosphere; Sealed tube;	General procedure: In a sealable reaction tube was combined tert-butyl 2-[(R)-5-bromo-2,3-dihydro-1H-inden-1-yl]-2,7-diazaspiro[3.5]nonane-7-carboxylate 3 (300 mg,0.71 mmol), <strong>[7554-65-6]4-methyl-1H-pyrazole</strong> 7b (88 mg, 1.07 mmol), tris(dibenzylideneacetone)dipalladium (65 mg, 0.071 mmol), 5-(di-tert-butyl-phosphanyl)-1',3',5'-triphenyl-1'H-[1,4']bipyrazolyl (72 mg, 0.14 mmol), and cesium carbonate (377 mg, 1.07 mmol). Anhydrous 1,4-dioxane (3 mL) was added and the mixture was purged with nitrogen for 10 min. The reaction was sealed and heated at 100 C overnight. The reaction was cooled to room temperature, and diluted with 150 mL of ethyl acetate. The organic solution was washed with water (100 mL), dried (MgSO4), filtered through a plug of Celite and concentrated under reduced pressure to give a yellow oil. The crude product was purified by silica gel chromatography eluting with 0100% ethyl acetate in heptanes to give 8b (239 mg, 79%) as a yellow solid. 1H NMR (500 MHz, CdCl3) 7.63 (s, 1 H) 7.517.45 (m, 2 H), 7.39 (dd, 1 H), 7.27 (d, 1 H), 3.913.87 (m, 1 H), 3.353.22 (m, 4 H), 3.153.06 (m, 4 H), 3.02 (dd, 1 H), 2.81 (dd, 1 H), 2.162.09 (m, 4 H), 1.961.85 (m, 1 H), 1.701.62 (m, 4 H), 1.42 (s, 9 H). MS (ESI): m/z 423.0 (M+H)+.

Reference： [1]Patent: US2011/230461,2011,A1 .Location in patent: Page/Page column 43
[2]Tetrahedron Letters,2012,vol. 53,p. 6351 - 6354,4

3
[ 1314319-10-2 ]
[ 123088-59-5 ]
[ 1334785-10-2 ]

Yield	Reaction Conditions	Operation in experiment
91%	With diisopropylamine;trisodium tris(3-sulfophenyl)phosphine; palladium diacetate; In water; acetonitrile; at 90℃; for 2h;	Preparation of 2-[(R)-5-(4-Carbamoyl-phenyl)-indan-1-yl]-2,7-diazaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester (4-1a) 2-((R)-5-Bromo-indan-1-yl)-2,7-diaza-spiro[3.5]nonane-7-carboxylic acid tert-butyl ester (3-1a, 500 mg, 1.19 mmol), <strong>[123088-59-5]4-carbamoylphenylboronic acid</strong> (587 mg, 3.56 mmol), Pd(OAc)2 (14 mg, 0.06 mmol) and TPPTS ligand (3,3',3-phosphinidynetris[benzenesulfonic acid] trisodium salt, 135 mg, 0.24 mmol) were suspended in 10 mL water and 5 mL acetonitrile. Diisopropylamine (291 mg, 2.85 mmol) was added, and the mixture was heated to 90 C. for 2 hours. The mixture was cooled to room temperature and was diluted with ethyl acetate (150 mL). The organic solution was washed with water (50 mL), dried (MgSO4), filtered through Celite and concentrated to give 499 mg (91%) of the title compound as a light pink powder. MS (ES+) 462.1 (M+H)+. 1H NMR (CD3OD) delta 1.42 (s, 9H), 1.64-1.74 (m, 4H), 1.83-1.96 (m, 1H), 2.17-2.30 (m, 1H), 2.80-2.93 (m, 1H), 3.10 (dt, 1H), 3.24-3.28 (m, 2H), 3.31-3.38 (m, 6H), 4.06 (dd, 1H), 6.79 (d, 1H), 7.39-7.49 (m, 2H), 7.53 (s, 1H), 7.67 (d, 2H), 7.73 (d, 1H), 7.89-7.94 (m, 2H).

Reference： [1]Tetrahedron Letters,2012,vol. 53,p. 6351 - 6354,4
[2]Patent: US2011/230461,2011,A1 .Location in patent: Page/Page column 39

4
[ 741709-63-7 ]
[ 1314319-10-2 ]
[ 1334785-12-4 ]

Yield	Reaction Conditions	Operation in experiment
54%	With sodium carbonate;tetrakis(triphenylphosphine) palladium(0); In 1,4-dioxane; water; at 95℃;Inert atmosphere; Reflux;	Preparation of 2-[(R)-5-(6-Cyano-pyridin-3-yl)-indan-1-yl]-2,7-diaza-spiro[3.5]nonane-7-carboxylic acid tert-butyl ester (4-1c) In a round-bottomed flask was combined 2-((R)-5-bromo-indan-1-yl)-2,7-diaza-spiro[3.5]nonane-7-carboxylic acid tert-butyl ester (3-1a, 1.50 g, 3.56 mmol), 5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine-2-carbonitrile (819 mg, 3.56 mmol), Pd(PPh3)4 (210 mg, 0.18 mmol), and K2CO3 (1.12 g, 7.83 mmol). A mixture of 27 mL 1,4-dioxane and 3 mL water (de-oxygenated with a nitrogen stream for 20 minutes) was added and the reaction was heated to 95 C. overnight. The reaction mixture was cooled to room temperature and was diluted with 200 mL ethyl acetate. The organic solution was washed with 50 mL water, dried (MgSO4), filtered through Celite and concentrated to give 2.7 g of a yellow oil. The crude material was purified using ISCO (Teledyne Isco Inc., Lincoln Nebr.) column chromatography, eluting with a 0-100% ethyl acetate in heptanes gradient. The title compound was obtained as a white solid (850 mg, 54%). MS (ES+) 445.1 (M+H)+. 1H NMR (CDCl3) delta 1.43 (s, 9H), 1.64-1.73 (m, 4H), 1.86-2.00 (m, 1H), 2.09-2.24 (m, 1H), 2.87 (dd, 1H), 3.01-3.10 (m, 1H), 3.10-3.19 (m, 4H), 3.27-3.36 (m, 4H), 3.95 (dd, 1H), 7.33-7.41 (m, 2H), 7.42-7.46 (m, 1H), 7.72 (dd, 1H), 7.94 (dd,1H), 8.89 (dd, 1H).

Reference： [1]Patent: US2011/230461,2011,A1 .Location in patent: Page/Page column 40

5
[ 1314319-10-2 ]
[ 36070-75-4 ]
[ 1334785-26-0 ]

Yield	Reaction Conditions	Operation in experiment
59%		Preparation of tert-Butyl 2-((R)-5-(5-cyanopyrazin-2-yl)-2,3-dihydro-1H-inden-1-yl)-2,7-diazaspiro[3.5]nonane-7-carboxylate (10-1a) To a solution of tert-butyl 2-[(1R)-5-bromo-2,3-dihydro-1H-inden-1-yl]-2,7-diazaspiro[3.5]nonane-7-carboxylate (3-1a, 700 mg, 1.66 mmol) in anhydrous dioxane (10 mL) was added bis(pinacolato)diboron (473 mg, 1.86 mmol) and potassium acetate (659 mg, 6.71 mmol). The mixture was purged with nitrogen for 15 minutes. Pd(dppf)Cl2 (62 mg, 0.07 mmol) was added and the reaction mixture was purged with nitrogen for an additional 15 minutes. The reaction was heated to 110 C. under nitrogen for 5 hours. TLC indicated the complete consumption of the starting material (3-1a). The reaction was cooled to room temperature and <strong>[36070-75-4]5-chloropyrazine-2-carbonitrile</strong> (278 mg, 1.99 mmol), Pd(dppf)Cl2 (62 mg, 0.07 mmol) and 5.81 mL of 2M aqueous K2CO3 solution (de-oxygenated with a stream of nitrogen for 15 minutes prior to addition) were added. The reaction was purged with nitrogen (3×) and was heated for 20 hours at 110 C. The reaction was cooled and concentrated in vacuo. The residue was partitioned between 50 mL of ethyl acetate and 50 mL of 1N NaOH solution. The organics layer was washed with 50 mL of brine, dried (Na2SO4) and concentrated to give crude product as black semi-solid. The crude product was purified via silca gel chromatography using a Combiflash ISCO purification system (Teledyne Corp., Lincoln, Nebr.) system, eluting with 0-100% EtOAc:heptanes to give the title compound as a brown solid (440 mg, 59%). MS (ES+) 446.3 (M+H)+. 1H NMR (DMSO-d6) delta 1.39 (s, 9H), 1.56-1.64 (m, 4H), 1.81-1.92 (m, 1H), 2.06 (dd, 1H), 2.77-2.87 (m, 1H), 2.92-3.04 (m, 3H), 3.12 (d, 2H), 3.24-3.28 (m, 4H), 3.86 (dd, 1H), 7.41 (d, 1H), 7.55 (d, 1H), 7.62-7.68 (m, 1H), 8.09 (s, 1H), 8.90 (s, 1H).

Reference： [1]Patent: US2011/230461,2011,A1 .Location in patent: Page/Page column 44

6
[ 1228561-27-0 ]
[ 1312131-48-8 ]
[ 1314319-10-2 ]

Yield	Reaction Conditions	Operation in experiment
90%		To a solution of <strong>[1228561-27-0](1R)-5-bromoindan-1-amine</strong> (SM-1, 1835 g, 8.66 mol) in anhydrous methanol (24 L) was added tert-butyl 4-(chloromethyl)-4-formylpiperidine-1-carboxylate (SM-3a, 2310 g, 8.83 mol). The mixture was stirred at 50 C. for 16 h, and cooled to rt. Sodium cyanoborohydride (1000 g, 15.9 mol) in THF (15 L) was added via a syringe pump over 2 hours. The mixture was stirred at 60 C. for 24 hours under nitrogen with a vent into a bleach bath. The reaction was cooled to 20 C. and transferred via a cannula into a vessel containing 24 L of 2.5M sodium hydroxide, and 30 L of DCM. The layers were separated and the aqueous layer was extracted with DCM (2×5 L). The aqueous layer was treated to destruct residual sodium cyanoborohydride. The combined organic layers were dried (MgSO4) and concentrated under reduced pressure. The crude material was slurried in MTBE (7 L) by stirring at 40 C. for 1 h and at rt for 1 h. The solid was filtered, and washed with MTBE (2×500 mL) and dried under vacuum oven at 50 C. to give the title product as a white crystals (3657 g, 90%). MS (ES+) 422.3 (M+H)+. 1H NMR (CDCl3) delta 1.44 (s, 9H), 1.67 (dd, 4H), 1.84-1.93 (m, 1H), 2.07-2.16 (m, 1H), 2.72-2.81 (m, 1H), 2.95-3.15 (m, 5H), 3.31 (dd, 4H), 3.85 (br s, 1H), 7.12 (d, 1H), 7.28 (br s, 1H), 7.35 (br s, 1H). [alpha]D20=+39.6 deg (c=1.06 mg/mL, MeOH).
90%		To a solution of <strong>[1228561-27-0](R)-5-bromo-2,3-dihydro-1H-inden-1-amine</strong> (1835 g, 8.66 mol) inanhydrous methanol (24 L) was added tert-butyl 4-(chloromethyl)-4-formylpiperidine-1-carboxylate (2310 g, 8.83 mol). The mixture was stirred at 50C for 16 h, and cooled to rt. Sodium cyanoborohydride (1000 g, 15.9 mol) in THF (15 L) was added via a syringe pump over 2 hours. The mixture was stirred at 60C for 24 hours under nitrogen with a vent into a bleach bath. The reaction was cooled to 20C and transferred via a cannulainto a vessel containing 24 L of 2.5M sodium hydroxide, and 30 L of DCM. The layers were separated and the aqueous layer was extracted with DCM (2 x 5 L). The aqueous layer was treated to destruct residual sodium cyanoborohydride. The combined organic layers were dried (Mg504) and concentrated under reduced pressure. The crude material was slurried in MTBE (7 L) by stirring at 40C for 1 h and at rt for 1 h. The solidwas filtered, and washed with MTBE (2 x 500 mL) and dried under vacuum oven at50C to give the title product as a white crystals (3657 g, 90%). MS (ES+) 422.3(M+H). 1H NMR (CDCI3) 1.44 (s, 9H), 1.67 (dd, 4H), 1.84-1.93 (m, 1H), 2.07-2.16 (m,1H), 2.72-2.81 (m,1 H), 2.95-3.15 (m, 5H), 3.31 (dd, 4H), 3.85 (brs, 1H), 7.12 (d, 1H),7.28 (br s, 1 H), 7.35 (br s, 1 H). [a] = +39.6 deg (c = 1.06 mgmL, MeOH).
74%		To a solution of <strong>[1228561-27-0](R)-5-bromoindan-1-amine</strong> (1835 g, 8.66 mol) in anhydrous methanol (24 L) was added tert-butyl 4-(chloromethyl)-4-formylpiperidine-1-carboxylate (2310 g, 8.83 mol). The mixture was stirred at 50 C for 16 h, and cooled to rt. Sodium cyanoborohydride (1000 g, 15.9 mol) in THF (15 L) was added via a syringe pump over 2 h. The mixture was stirred at 60 C for 24 h under nitrogen with a vent into a bleach bath. The reaction was cooled to 20 C and transferred via a cannula into a vessel containing 24 L of 2.5M sodium hydroxide, and 30 L of DCM. The layers were separated and the aqueous layer was extracted with DCM (2 x 5L). The aqueous layer was treated to destruct residual sodium cyanoborohydride. The combined organic layers were dried (MgSO4) and concentrated under reduced pressure. The crude material was slurried in methyl tert-butyl ether (7 L) by stirring at 40 C for 1 h and at rt for 1 h. The solid was filtered, and washed with methyl tert-butyl ether (2 x 500 mL) and dried in a vacuum oven at 50 C to give 3 (2699 g, 74%) as white crystals. 1H NMR (500 MHz, Cd3Od): delta 7.42 (s, 1 H), 7.32 (d, J = 10 Hz, 1 H), 7.26 (d, J = 10.0 Hz, 1 H), 4.01-3.97 (m, 1 H), 3.36 (s, 4 H), 3.28-3.30 (m, 2 H), 3.24 (d, J = 10.0 Hz, 2 H), 3.09-3.03 (m, 1 H), 2.86-2.80 (m, 1 H), 2.25-2.18 (m, 1 H), 1.92-1.86 (m, 1 H), 1.72-1.70 (m, 4 H), 1.45 (s, 9 H); 13C NMR (125 MHz, Cd3Od): delta 155.3, 147.3, 142.7, 129.1, 127.9, 126.1, 119.2, 80.0, 71.3, 62.2, 51.5, 35.5, 33.8, 29.9, 29.1, 27.5; HRMS: m/z 421.1480 (calc 421.1485 for C21H29BrN2O2+ H); [alpha]20D= +39.6 deg (c = 1.06 mg/mL, MeOH).

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 5410 - 5414
[2]Patent: US2011/230461,2011,A1 .Location in patent: Page/Page column 36
[3]Patent: WO2013/182933,2013,A1 .Location in patent: Page/Page column 19
[4]ACS Medicinal Chemistry Letters,2014,vol. 5,p. 474 - 479
[5]Tetrahedron Letters,2012,vol. 53,p. 6351 - 6354,4

7
[ 1314319-10-2 ]
[ 1072945-86-8 ]
[ 1414782-45-8 ]

Yield	Reaction Conditions	Operation in experiment
26%	With tetrakis(triphenylphosphine) palladium(0); potassium carbonate; In 1,4-dioxane; water; at 95℃; for 18h;Inert atmosphere;	To a solution of tert-butyl 2-[(R)-5-bromo-2,3-dihydro-1H-inden-1-yl]-2,7-diazaspiro[3.5]nonane-7-carboxylate 3 (800 mg, 1.9 mmol), <strong>[1072945-86-8](6-(methoxycarbonyl)pyridin-3-yl)boronic acid</strong> 5v (600 mg, 2.28 mmol), Pd(PPh3)4 (112 mg, 0.085 mmol) and K2CO3 (595 mg, 4.18 mmol) in 1,4-dioxane (27 mL) and water (3 mL) (de-gassed with N2 for 20 min) was heated under reflux for 18 h. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate (150 mL), washed with water (50 mL), and the organic layer was dried (MgSO4), filtered and concentrated under reduced pressure to give the crude compound. This material was purified by silica gel chromatography with a gradient of 0-30% methanol in dichloromethane to give 6v (232 mg, 26%) as an orange glass. 1H NMR (400 MHz, CdCl3): delta 8.92 (dd, J = 2.2, 0.7 Hz, 1 H), 8.18 (dd, J = 8.2, 0.8 Hz, 1 H), 7.98 (dd, J = 8.1, 2.2 Hz, 1 H), 7.65 (dd, J = 12.0, 1.5 Hz, 1 H), 7.57-7.51 (m, 1 H), 7.49-7.41 (m, 1 H), 4.02 (s, 3 H), 3.96 (d, J = 2.5 Hz, 1 H), 3.38-3.29 (m, 4 H), 3.21-3.04 (m, 4 H), 2.93-2.81 (m, 1 H), 2.24-2.06 (m, 2 H), 2.00-1.90 (m, 1 H), 1.75-1.65 (m, 4 H), 1.44 (s, 9 H); MS (ESI): m/z 478.1 (M+H)+.

Reference： [1]Tetrahedron Letters,2012,vol. 53,p. 6351 - 6354,4

8
[ 3435-25-4 ]
[ 1314319-10-2 ]
[ 1334785-06-6 ]

Yield	Reaction Conditions	Operation in experiment
86%		To a 50 mL flask charged with (R)-tert-butyl 2-(5-bromo-2,3-dihydro-1 H-inden-1-yl)-2,7-diazaspiro[3.5]nonane-7-carboxylate (4.0 g, 9.49 mmol) was addedbis(triphenylphosphine)palladium(l I) chloride (0.17 g, 0.24 mmol), potassium acetate (3.73 g, 37.97 mmol), bis(pinacolato)diboron (2.65 g, 10.44 mmol) followed by degassing via vacuum then backfilling with nitrogen 5 times. De-oxygenated (nitrogen stream for 30 minutes prior to addition) toluene (40 mL) was added to the mixture and the reaction was heated at 100C for 1.5 hours. The reaction was monitored for completion by H PLC. Upon formation of the boronic ester intermediate, the reaction was cooled to 40C and charged with a degassed solution of 4 M sodium hydroxide (11.87 mL, 47.46 mmol) followed by addition of <strong>[3435-25-4]4-chloro-6-methylpyrimidine</strong> (1.53 g, 11.87mmol). The resulting mixture was then heated to 90C for 5 hours under nitrogen. The reaction was cooled to room temperature and charged with water (25 mL). After stirring for 20 minutes, the mixture was filtered to remove black solids. The organic layer was extracted to an aqueous solution containing 1.5 equiv of HCI (40 mL). The organic layer was removed and the resulting solution was treated with (4 g) ISOLUTE Ultra Pure Si-Thiol silica gel for 1.5 hours and filtered. The aqueous solution was adjusted to pH 7.8 with 4N NaOH and extracted with toluene (40 mL). The toluene layer was concentrated to approximately 15 mL under vacuum at 45C and heptane (75 mL) was added slowly and the mixture was stirred at 20C for 1 hour. The product was filtered and dried under vacuum at 45C for 8 hours to afford the title compound as a white solid (3.56 g, 86%).MS(ES-f-)435.5(M-f-H). 1H NMR(CDCl3) 1.46 (s,9 H), 1.70- 1.74(m, 4 H), 1.90-2.01 (m, 1 H), 2.13-2.26 (m, 1 H), 2.59 (s, 3 H), 2.84-2.93 (m, 1 H), 3.04-3.21 (m, 5H), 3.30 - 3.38 (m, 4 H), 3.95 - 4.02 (m, 1 H), 7.40 (d, 1 H), 7.56 (s, 1 H), 7.87 (d, 1 H),7.95 (s, 1 H), 9.12 (s, 1 H).

Reference： [1]Patent: WO2013/182933,2013,A1 .Location in patent: Page/Page column 19; 20

Same Skeleton Products

Related Products

Historical Records

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 1314319-10-2 ] {[proInfo.proName]}

Quality Control of [ 1314319-10-2 ]

Related Doc. of [ 1314319-10-2 ]

Product Details of [ 1314319-10-2 ]

Safety of [ 1314319-10-2 ]

Application In Synthesis of [ 1314319-10-2 ]

[ 1314319-10-2 ] Synthesis Path-Downstream 1~8

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry